抗C-C动机趋化素受体8(CCR8)-开发平台分析:2022年

本报告提供抗CCR8市场机会的主要的竞争分析，开发平台医药品的简介的企业，临床试验，其他的发展趋势等彙整资料。

样本图

目录

概要

抗CCR8标的背景

• CC动机趋化素受体8(CCR8)- 概要
• 治疗标的的CCR8
• CCR8临床性展望
• CCR8标靶治疗相关的安全上的疑虑

抗CCR8开发平台分析，各相

• 抗CCR8开发- 概要
• 开发中产品，各开发阶段
• 抗CCR8竞争情形环境，各相
• 开发中产品，各企业
• 开发中产品，适应症及各相
• 抗CCR8临床及法规的单剂疗法及联合治疗
• 抗CCR8资产，适应症及各相
• 抗CCR8临床及法规的时间轴

抗CCR8授权，收购，及合作契约

抗形势开发平台状况

• 简介比较概要
• 抗CCR8开发平台的药物简介
  • 第一/二阶段
    • BMS-986340
    • S-531011
    • LM-108
  • 第一阶段
    • ICP B05
    • BAY 3375968
    • GS 1811
    • IPG 7236
    • ABBV 514
  • 前临床
    • FPA157
    • HBM1022
    • CCR8 Treg计划
    • ZL-1218
    • SRF 114
    • BCG 005
    • GB2101
    • FG-3136
    • CHS-3318
  • 药物研发
    • 抗CCR8抗体

抗CCR8 SWOT分析

抗CCR8产品的定位

附录

The Anti-CCR8 report covers the anti-CCR8 market opportunity providing Key Competitive Analysis, 18+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. The Anti-CCR8 report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

SAMPLE VIEW

The Anti-CCR8-mediated Treg depletion specifically in tumor tissues for a limited period could avoid deleterious autoimmunity and immunopathology in mice, despite CCR8 expression by some tissue-resident Tregs (46). This lack of immunological adverse effects can be attributed not only to the selective depletion of tumor-reactive Tregs by anti-CCR8 mAb but also to the differences in the antigenicity of normal self-antigens versus quasi-self-tumor antigens, and the differences between the tumor microenvironment and the normal tissue.

In this report, Mellalta Meets provides an in-depth analysis of Anti-CCR8 covering discovery, preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidate Anti-CCR8 products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Bristol-Myers Squibb, Shionogi, LaNova Medicines, InnoCare Pharma/Keymed Biosciences, Bayer, and many more which have robust clinical pipelines of Anti-CCR8 candidates.

As per analysis, the development pipeline is full of molecules like small molecules, antibodies, and combination therapies.

Key Highlights of the Anti-CCR8 Report:

• There are ~8 products in the Pre-clinical stage of development, and ~5 in the Phase 1 stage of development representing 41.18%, and 29.41% respectively of the total share of the developing Anti-CCR8 landscape. The remaining 29.41% has been contributed by Phase 1/2 (17.65%), and Discovery (11.76%) assets.

• The pipeline of Anti-CCR8 is dominated by biotech companies headquartered in China with Chinese companies holding the top 7 positions. They represent ~38.89% of all the pipeline Anti-CCR8 in clinical stages.

• Anti-CCR8 pipeline landscape includes 47% of Monotherapy trials and 53% of Combination Trials

• The pipeline of Anti-CCR8 is dominated by pre-clinical (8); Phase 1 (5); Phase 1/2 (3) assets and Discovery (1) assets.

• To be continued....

Report Coverage:

• Indication Prioritisation: Anti-CCR8 market potential based on Indications

• Business Transactions & Strategies: Key collaborations and deal values

• Anti-CCR8 Pipeline Development: Product Profiles, Clinical Trials & Results

• Anti-CCR8 Acquisition Targets

• Anti-CCR8 Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Anti-CCR8 Target BACKGROUND

• C-C Motif Chemokine Receptor 8 (CCR8)-Overview
• CCR8 as a Therapeutic Target
• Clinical Prospects of CCR8
• Safety Concerns Related to CCR8-Targeted Therapies

Anti-CCR8 PIPELINE ANALYSIS by Phases

• Anti-CCR8 Development - Overview
• Pipeline Products by Stage of Development
• Anti-CCR8 Competitive Landscape by Phases
• Pipeline Products by Company
• Pipeline Products by Indication and Phases
• Anti-CCR8 Clinical & Regulatory Monotherapy & Combinations
• Anti-CCR8- Assets by Indication/Phase
• Anti-CCR8 Clinical & Regulatory Timelines

Anti-CCR8 LICENSING, ACQUISITION, AND COLLABORATION DEALS

• Anti-CCR8 Licensing, Acquisition, and Deal values
• Anti-CCR8 Licensing by Transaction type and total amount size by Phases

Anti-CCR8 Pipeline Landscape

• Profile Comparisons At-a-glance
• Anti-CCR8 Pipeline Drug Profiles
  • Phase I/II
    • BMS-986340 (Bristol-Myers Squibb)
      • Product Profile & Description
      • Clinical Trials
      • Other Developments
    • S-531011 (Shionogi)
      • Product Profile & Description
      • Clinical Trials
      • Other Developments
    • LM-108 (LaNova Medicines)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Phase I
    • ICP B05 (InnoCare Pharma/Keymed Biosciences)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • BAY 3375968 (Bayer)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • GS 1811 (Gilead Sciences)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • IPG 7236 (Nanjing Immunophage Biotech Co., Ltd)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
    • ABBV 514 (AbbVie)
      • Product Profile & Description
      • Clinical Trials
      • Collaborations
      • Other Developments
  • Pre-clinical
    • FPA157 (Amgen)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • HBM1022 (Harbour BioMed)
      • Product Profile & Description
      • Other Developments
    • CCR8 Treg program (Oncurious)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • ZL-1218 (ZAI Lab)
      • Product Profile & Description
      • Other Developments
    • SRF 114 (Surface Oncology)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • BCG 005 (Biocytogen Pharmaceuticals (Beijing) Co., Ltd./LiberoThera Co., Ltd)
      • Product Profile & Description
      • Collaborations
      • Other Developments
    • GB2101 (Genor Biopharma Co. Ltd.)
      • Product Profile & Description
      • Other Developments
    • FG-3136 (HiFiBiO Therapeutics/FibroGen)
      • Product Profile & Description
      • Other Developments
      • Collaborations
    • CHS-3318 (Coherus BioSciences)
      • Product Profile & Description
      • Other Developments
  • Discovery
    • Anti-CCR8 Antibody (Domain Therapeutics)
      • Product Profile & Description
      • Other Developments
      • Patents Filed in Recent Years

Anti-CCR8 SWOT Analysis

Anti-CCR8 Products Positioning

Appendix

• About us